The Swiss life-sciences company said it expected accelerated sales growth in the fourth quarter on the back of the timing of ...

Diabetic retinopathy appears to be more common in young people than earlier thought, leaving more of them at risk for eye ...

A minorities-only study on a dual-action therapy for diabetic macular edema found Hispanic and Latino patients not only ...

Sandoz, Eli Lilly, Bayer, and Genentech executives tell what strikes them about the 2024 presidential race — and how the ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

The allergy treatment market is set to experience robust growth, with an estimated valuation of US$ 20.20 billion in 2022 and ...

Some of the soundbite health care policy proposals that candidates bring up for short-term political impact could in practice ...

Genentech, a member of the Roche (RHHBY), announced topline one-year results from the open-label, single-arm Phase IV ...

Regulators are supposed to abide by society's “bargain” with them: Civil servants are granted lifetime tenure and protected ...